1) Lenneman CG, et al : Cardio-Oncology : An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res 118 : 1008-1020, 2016
2) Motzer RJ, et al : Sunitinib Versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med 356 : 115-124, 2007
3) Chu TF, et al : Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib. Lancet 370 : 2011-2019, 2007
4) Nhola LF, et al : Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr 32 : 267-276, 2019
5) Hall PS, et al : The Frequency and Severity of Cardiovascular Toxicity from Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC Heart Fail 1 : 72-78, 2013
6) Narayan V, et al : Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res 23 : 3601-3609, 2017
7) Schmidinger M, et al : Cardiac Toxicity of Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol 26 : 5204-5212, 2008
8) Plana JC, et al : Expert Consensus for Multimodality Imaging Evaluation of Adult Patients During and After Cancer Therapy : A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014
9) Lang RM, et al : Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39, 2015
10) Ewer MS, et al : Type II Chemotherapy-Related Cardiac Dysfunction : Time to Recognize a New Entity. J Clin Oncol 23 : 2900-2902, 2005